Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

Phase 2

Tundra lists 5 Phase 2 clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07283731

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-02

1 state

Phase 2
Zanzalintinib
Pembrolizumab
+2
NOT YET RECRUITING

NCT07783594

Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma

To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-02

1 state

Randomized
Phase 2
Epcoritamab
+4
NOT YET RECRUITING

NCT07511023

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-02

1 state

Phase 2
Sacituzumab Tirumotecan
Refractory Metastatic
+2
RECRUITING

NCT07382739

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Gender: All

Updated: 2026-09-18

1 state

Phase 2
Radiotherapy-Induced Immune Priming
Elranatamab
+4
NOT YET RECRUITING

NCT07610525

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-28

1 state

Triple Negative Breast Cancer
Blood and Image Guided
Optimization of Neoadjuvant Therapy
+1